Loading…
← CockpitCompetitor Analysis › 600750.SS China Resources Jiangzhong Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A600750.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other

Jiangxi TCM maker best known for Jianwei Xiaoshi Pian, a widely sold digestive-aid tablet, under the China Resources group.

≈ A Chinese TCM digestive-remedy maker (like a herbal Tums)Momentum leader 90
Mkt cap
$2.27B
US dollars, full cap
Free float
51%
of shares outstanding
$/day
$18.2M
20-day average traded
Fwd P/E
16.5×
forward earnings
ROIC−WACC
+10.3 pp
WACC 5.0%
Hurdle
-14 pp
Req g minus delivered
Next earnings
121 days
19 Mar 2027
Close · CNYCN¥23.88
1D+1.3%
1W+5.2%
1M+0.9%
3M-0.8%
6M+3.8%
YTD+3.1%
1Y+11.9%
ATR %2.4%
52w lowhigh14.2% off high

What China Resources Jiangzhong Pharmaceutical does

Jiangxi TCM maker best known for Jianwei Xiaoshi Pian, a widely sold digestive-aid tablet, under the China Resources group.

Relies on one over-the-counter tablet for much of its revenue and spends heavily on advertising and pharmacy-chain promotion to keep it in front of shoppers, so marketing outlay and a single brand's fortunes shape results. Sold mainly through pharmacy chains and distributors.

In one line: A Chinese TCM digestive-remedy maker (like a herbal Tums).

Products and services

  • Jianwei Xiaoshi digestive tablets
  • Other OTC TCM health products

Customers

  • Retail pharmacies

Where it sits in the supply chain

  • Pharmaceuticals
  • Traditional Chinese medicine
  • OTC digestive and health products

What could go right

  • OTC digestive-remedy demand

What could go wrong

  • OTC price competition

Moat: narrow (brand, distribution). Long-established OTC digestive brand with China Resources group distribution support.

Headquarters: Nanchang, Jiangxi, China · Employees: 4,352

Named competitors

China Resources Jiangzhong Pharmaceutical at a glance

Size China Resources Jiangzhong Pharmaceutical (600750.SS) is a China Health Care company (Pharmaceuticals: Other) with a market value of $2.27B, the 1061st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥23.88 on 18 Nov 2026.

Performance Over six months the shares gained 3.8%, against -3.5% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue fell 10.2% over the last twelve months (peer median +10.2%); the operating margin is 23.6% (peer median 15.0%).

Valuation It trades at 16.5× forward earnings against a peer median of 16.9× (9th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 10.3 points above its cost of capital (5.0% WACC).

Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).

Relative performance

10011021 May 202621 Aug 202618 Nov 2026600750.SS 106Peer median 96
Six months, rebased to 100: China Resources Jiangzhong Pharmaceutical against the median of its 20 peers (local-currency closes).

China Resources Jiangzhong Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.95BCN¥4.18BCN¥4.40BCN¥4.52BCN¥3.85B
Revenue growth—-5%-3%+17%—
Gross profitCN¥2.65BCN¥2.67BCN¥2.73BCN¥2.82BCN¥2.42B
EBITDAn/aCN¥1.17BCN¥1.03BCN¥966MCN¥744M
Net incomeCN¥841MCN¥907MCN¥788MCN¥719MCN¥598M
Free cash flowCN¥891MCN¥738MCN¥569MCN¥870MCN¥730M
Capital expenditureCN¥229MCN¥281MCN¥291MCN¥211MCN¥346M
Total debtCN¥637MCN¥355MCN¥6.29MCN¥56.6MCN¥89.1M

Quarterly statements and history in the cockpit →

China Resources Jiangzhong Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%6000621112GRANULES300146600056002317300363BHC600216SUDEEPPHRM002603JWEL6472BIOG-BPHMCRON002275600750.SS6-month return →1-month return →
Up and to the right = strong over both horizons. China Resources Jiangzhong Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×50×6000621112GRANULES300146002317BHC600216SUDEEPPHRM002603JWEL6472BIOG-BPHMCRON2142600750.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. China Resources Jiangzhong Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%6000621112GRANULES300146002317300363BHCJWEL6472BIOG-BPHMCRON2142600750.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. China Resources Jiangzhong Pharmaceutical is the large dot.

China Resources Jiangzhong Pharmaceutical competitors and peer comparison

Head to head with its named competitors (600750.SS vs 600129.SS vs 000999.SZ vs 000538.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
China Resources Jiangzhong Pharmaceutical 600750.SS$2.27B+4%-10%24%16.5×-1.9%
Chongqing Taiji Industry (Group) 600129.SS$982M-20%-4%2%69.8×n/a
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ$6.59B+6%+4%14%13.2×-6.2%
Yunnan Baiyao 000538.SZ$15.0B+11%+5%11%18.3×-0.2%

How China Resources Jiangzhong Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

China Resources Jiangzhong Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600750.SSPeer medianRank in peer set
1-month return+0.9%-1.3%7th highest of 21
6-month return+3.8%-3.5%9th highest of 21
Distance from 52-week high-14.2%-26.3%7th highest of 21
Revenue growth (TTM)-10.2%+10.2%2nd lowest of 21
Operating margin23.6%15.0%7th highest of 21
Forward P/E16.5×16.9×9th cheapest of 17
Growth the price implies (Req g, 7 yrs)-1.9%2.1%6th least demanding of 20
Growth delivered (Del g)+11.6%+5.9%6th highest of 20
Hurdle (Req g minus delivered)-13.5 pp-8.0 pp7th least demanding of 20
ROIC minus cost of capital+10.3 pp+2.7 pp6th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
China Resources Jiangzhong Pharmaceutical 600750.SSChina$2.27B+4%-10%24%16.5×-1.9%+11.6%
China Resources Double-Crane Pharmaceutical 600062.SSChina$2.35B-14%-1%13%9.3×-9.1%+5.3%
Health and Happiness (H&H) International 1112.HKHong Kong$2.15B+108%+24%16%13.2×-1.7%+4.4%
Granules India GRANULES.NSIndia$2.12B+4%+22%17%24.8×23.6%+10.6%
By-health 300146.SZChina$2.56B-1%+10%11%24.7×4.8%+0.6%
China Meheco 600056.SSChina$1.90B-16%+2%3%n/a-1.3%-2.1%
Jilin Aodong Pharmaceutical 000623.SZChina$2.97B-7%-4%-13%n/a5.0%+1.0%
Guangdong Zhongsheng Pharmaceutical 002317.SZChina$3.00B+11%-14%9%91.7×33.8%+5.9%
Porton Pharma Solutions 300363.SZChina$1.66B+37%+6%-2%n/a2.1%+10.4%
Bausch Health Companies BHC.TOCanada$3.27B+66%+10%27%2.0×-14.8%+5.9%
Tibet Cheezheng Tibetan Medicine 002287.SZChina$1.58B-17%-7%28%n/a-1.9%+10.4%
Zhejiang Medicine 600216.SSChina$1.51B-26%-6%7%11.5×-7.8%+3.9%
Sudeep Pharma SUDEEPPHRM.NSIndia$1.45B+85%+27%33%69.1×n/an/a
Shijiazhuang Yiling Pharmaceutical 002603.SZChina$3.83B-7%+32%21%17.5×-3.9%-2.2%
Jamieson Wellness JWEL.TOCanada$1.32B+32%+12%13%20.6×13.5%+15.3%
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%10.8×3.5%+60.2%
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%31.0×1.5%+15.5%
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%41.4×10.6%-3.9%
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%12.8×-8.7%+5.5%

Questions

Who are China Resources Jiangzhong Pharmaceutical's main competitors?
Named competitors: Chongqing Taiji Industry (600129.SS), China Resources Sanjiu (000999.SZ), Yunnan Baiyao (000538.SZ). The cockpit's measured peer set (industry) also includes China Resources Double-Crane Pharmaceutical (600062.SS), Health and Happiness (H&H) International (1112.HK), Granules India (GRANULES.NS), By-health (300146.SZ), China Meheco (600056.SS), Jilin Aodong Pharmaceutical (000623.SZ).
Is China Resources Jiangzhong Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 16.5× against a peer median of 16.9×, 9th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has China Resources Jiangzhong Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +3.8% against -3.5% for the median peer; over one year +11.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.